Background : Programmed death ligand 1 (PD-L1) expression is a reliable biomarker of immune-checkpoint inhibitors (ICI) in multiple cancer types including urothelial carcinoma (UC). A 22C3 pharmDx immunohistochemistry was particularly determined by using the combined positive score (CPS) in UC. A challenging issue regarding the manual scoring of CPS by a pathologist is in determining the representative area to read. This requires substantial time and effort and may lead to inter-observer variation. We developed an artificial intelligence (AI)-powered CPS analyzer, to assess CPS in whole-slide images (WSI) and validated its performance by comparing against a consensus of pathologists’ readings.
Methods : An AI-powered CPS analyzer, Lunit SCOPE PD-L1, has been trained and validated based on a total of 3,326,402 tumor cells, lymphocytes, and macrophages annotated by board-certified pathologists for PD-L1 positivity in 1200 WSI stained by 22C3. After excluding the in-house control tissue regions, the WSIs were divided into patches, from which a deep learning-based model was trained to detects the location and PD-L1 positivity of tumor cells, lymphocytes, and macrophages, respectively. Finally, the patch-level cell predictions were aggregated for CPS estimation. The performance of the model was validated on an external validation UC cohort consisting of two institutions: Boramae Medical Center (BMC, n = 93) and Seoul National University Bundang Hospital (SNUBH, n = 100). Three uropathologists independently annotated the CPS of the external validation cohorts, and a consensus of CPS was determined by determination of their mean values.
Results : The AI-model predicts CPS accurately in an internal validation cohort as the area under the curves (AUC) values to predict PD-L1-positive tumor cell, PD-L1-positive lymphocytes or macrophages, PD-L1-negative tumor cell, and PD-L1-negative lymphocytes or macrophages were 0.929, 0.855, 0.885, and 0.872, respectively. There was a significant positive correlation between CPS by AI-model and consensus CPS by 3 pathologists in the external validation cohort (Spearman coefficient = 0.914, P< 0.001). Concordance of AI-model and pathologists' consensus to call CPS ≥ 10 was 88.1%, which was similar to that of either 2 of 3 pathologists (84.5%, 86.5%, and 90.7%). The concordance rate was not significantly different according to data source (BMC: 88.2% versus SNUBH: 88.0%, P = 1.00), but was significantly different according to type of surgery [surgical resection (cystectomy, nephrectomy, and ureterectomy): 92.3% versus transurethral resection: 81.3%, P = 0.0244].
Conclusions : Lunit SCOPE PD-L1, AI-powered CPS analyzer, can detect PD-L1 expression in tumor cells, lymphocytes or macrophages highly accurately compared to uropathologists.
Jeong Hwan Park, Kyu Sang Lee, Euno Choi, Wonkyung Jung, Jaehong Aum, Sergio Pereira, Seonwook Park, Minuk Ma, Seungje Lee, Eunji Baek, Eun-Jihn Roh, Seunghwan Shin, Kyunghyun Paeng, Donggeun Yoo, Chan-Young Ock
Abstract: Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Reducing Domain Gap by Reducing Style Bias
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Abstract : Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Abstract : AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Analyzer Reduces Inter-observer Variation in PD-L1 Tumor Proportion Score of Non-Small Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...
Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals immune-excluded phenotype is correlated with TGF-beta pathway related genomic aberrations